← All trials
NCT06455280
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 11, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Mar 31, 2026
- First posted
- Jun 12, 2024
- Last posted
- Nov 12, 2024
- Enrollment
- 8
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Columbia UniversityLead sponsor
- Columbia UniversitySponsor investigator
- ITB-Med LLCCollaborator
- Columbia UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.